These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 33908026

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC, Bebin EM, Checketts D, Chez M, Flamini R, Marsh ED, Miller I, Nichol K, Park Y, Segal E, Seltzer L, Szaflarski JP, Thiele EA, Weinstock A, CBD EAP study group.
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [Abstract] [Full Text] [Related]

  • 3. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
    Gunning B, Mazurkiewicz-Bełdzińska M, Chin RFM, Bhathal H, Nortvedt C, Dunayevich E, Checketts D.
    Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
    [Abstract] [Full Text] [Related]

  • 4. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
    García-Peñas JJ, Gil Nagel-Rein A, Sánchez-Carpintero R, Villanueva-Haba V.
    Rev Neurol; 2021 Sep 10; 73(S01):S1-S8. PubMed ID: 34486101
    [Abstract] [Full Text] [Related]

  • 5. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Nabbout R, Arzimanoglou A, Auvin S, Berquin P, Desurkar A, Fuller D, Nortvedt C, Pulitano P, Rosati A, Soto V, Villanueva V, Cross JH.
    Seizure; 2023 Aug 10; 110():78-85. PubMed ID: 37331197
    [Abstract] [Full Text] [Related]

  • 6. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
    Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR.
    Lancet Neurol; 2016 Mar 10; 15(3):270-8. PubMed ID: 26724101
    [Abstract] [Full Text] [Related]

  • 7. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
    Talwar A, Estes E, Aparasu R, Reddy DS.
    Exp Neurol; 2023 Jan 10; 359():114238. PubMed ID: 36206805
    [Abstract] [Full Text] [Related]

  • 8. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S, Trinka E, Russo E, Striano P, Citraro R, Silvestrini M, Brigo F.
    Drugs Today (Barc); 2019 Mar 10; 55(3):177-196. PubMed ID: 30938373
    [Abstract] [Full Text] [Related]

  • 9. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R.
    Epilepsy Behav; 2015 Jun 10; 47():138-41. PubMed ID: 25935511
    [Abstract] [Full Text] [Related]

  • 10. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
    Lattanzi S, Trinka E, Striano P, Rocchi C, Salvemini S, Silvestrini M, Brigo F.
    CNS Drugs; 2021 Mar 10; 35(3):265-281. PubMed ID: 33754312
    [Abstract] [Full Text] [Related]

  • 11. Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea.
    Koo CM, Kim SH, Lee JS, Park BJ, Lee HK, Kim HD, Kang HC.
    J Korean Med Sci; 2020 Dec 28; 35(50):e427. PubMed ID: 33372424
    [Abstract] [Full Text] [Related]

  • 12. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
    Lattanzi S, Zaccara G, Russo E, La Neve A, Lodi MAM, Striano P.
    Expert Rev Neurother; 2021 Jan 28; 21(1):99-110. PubMed ID: 33026899
    [Abstract] [Full Text] [Related]

  • 13. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
    Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, GWPCARE3 Study Group.
    N Engl J Med; 2018 May 17; 378(20):1888-1897. PubMed ID: 29768152
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
    Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M.
    Drugs; 2018 Nov 17; 78(17):1791-1804. PubMed ID: 30390221
    [Abstract] [Full Text] [Related]

  • 15. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, GWPCARE4 Study Group.
    Lancet; 2018 Mar 17; 391(10125):1085-1096. PubMed ID: 29395273
    [Abstract] [Full Text] [Related]

  • 16. Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
    Wechsler RT, Burdette DE, Gidal BE, Hyslop A, McGoldrick PE, Thiele EA, Valeriano J.
    Epilepsia Open; 2024 Oct 17; 9(5):1632-1642. PubMed ID: 39007525
    [Abstract] [Full Text] [Related]

  • 17. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
    Patsalos PN, Szaflarski JP, Gidal B, VanLandingham K, Critchley D, Morrison G.
    Epilepsia; 2020 Sep 17; 61(9):1854-1868. PubMed ID: 32918835
    [Abstract] [Full Text] [Related]

  • 18. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS.
    Epilepsy Curr; 2019 Sep 17; 19(2):93-95. PubMed ID: 30955420
    [Abstract] [Full Text] [Related]

  • 19. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW, Borgelt LM, Blackmer AB.
    Ann Pharmacother; 2019 Jun 17; 53(6):603-611. PubMed ID: 30616356
    [Abstract] [Full Text] [Related]

  • 20. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
    Hahn CD, Jiang Y, Villanueva V, Zolnowska M, Arkilo D, Hsiao S, Asgharnejad M, Dlugos D.
    Epilepsia; 2022 Oct 17; 63(10):2671-2683. PubMed ID: 35841234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.